In the midst of a contentious battle for control over Hanmi Group, Lim Jong-yoon and Lim Jong-hoon -- the sons of the company founder and the late Lim Sung-ki -- appealed for shareholders' support and promised to elevate Hanmi Pharm into a powerhouse capable of generating 1 trillion won ($754.2 mill
The International Vaccine Institute (IVI) said it started transferring related technology for the development of a simplified oral cholera vaccine (OCV-S) to Biological E (BE), a leading vaccine and pharmaceutical company in India.The agreement comes after IVI and BE signed a technology license agre
Handok hosted the “APRO Symposium" on Tuesday at the Grand Intercontinental Seoul Parnas to celebrate the launch of Aprovasc, a hypertension treatment.The symposium, organized to commemorate the launch of Aprovasc, the first irbesartan and amlodipine combination drug in Korea, introduced the results
In a recent surge of shareholder-friendly moves, Korean pharmaceutical and biotech firms are ramping up their efforts to return value to their investors as they approach their annual shareholder meetings.Among the notable actions are substantial share buybacks and plans to enhance dividend payouts,
Celltrion Pharm has moved closer to launching Godex Max Tablets, the successor to its flagship drug, Godex Capsules.Market insiders are watching with interest to see if the company can revitalize itself through the launch of a new drug, given its somewhat disappointing sales performance last year.On
LG Chem has entered the domestic market for treating excess fat under the chin.LG Chem has announced the launch of Bellacholine (deoxycholic acid), an injectable drug designed to target submental fat. Bellacholine is intended for the treatment of moderate to severe protrusion or excess submental fat
The developers of the innovative new drug Enhertu (trastuzumab deruxtecan) have recently ended price negotiations with the National Health Insurance Service (NHIS) to receive reimbursement as early as next month.On Monday, the NHIS announced the settlement of Enhertu’s price bargaining by updating i
D&D Pharmatech, a Korean biotech company, said it expanded its collaboration with the U.S.-based Metsera for new treatments. This expansion includes amendments to a previously established agreement for an oral obesity treatment and the initiation of a new global technology transfer agreement for an
Lee Jin-a was appointed as the first Korean President and CEO of Bayer Korea in October of last year, a noteworthy event in the company's history spanning nearly 70 years. This appointment highlights the changing dynamics and strategic priorities of the Korean healthcare industry within the multinat
Bayer Korea's Kerendia (ingredient: finerenone), a novel non-steroidal mineralocorticoid receptor antagonist (MRA), is garnering significant attention from local physicians as a potential game-changer in the treatment of chronic kidney disease (CKD) associated with type 2 diabetes.The drug, which ta
Sales of Korean erectile dysfunction treatments hit all-time high in 2023 for the third consecutive year, with local pharmaceutical companies having around 90 percent of the market share.Leading the charge were Korean generic drugs like Hanmi Pharm's Palpal and Gugu, and Chong Kun Dang's Sendom, sig
Boryung Pharmaceutical said it has signed a memorandum of understanding with MirimGENE, a drug development company, to jointly develop innovative new drugs.MirimGENE develops new drugs to treat intractable infections and immune diseases by targeting the endogenous innate immune activator WARS1.Based
Obesity is becoming a serious problem in Korea.A recent statistical report published by the Ministry of Health and Welfare and the Korea Health Promotion Institute on Monday highlighted a worrying obesity trend in the aftermath of the Covid-19 pandemic, showing a sharp rise in obesity rates across a
The Korean Society for the Study of Obesity (KSSO) is now busy revising its guidelines ahead of Novo Nordisk's anticipated domestic launch of its obesity treatment Wegovy (semaglutide) late this year.According to a recent seminar of the Guidelines Committee at the KSSO’s 59th spring conference, the
Korean pharmaceutical companies are announcing their general shareholders’ meeting schedules.According to the Kosdaq Listed Companies Association, the key dates for shareholder meetings in 2024 are March 22, 27, and 29, when the domestic drugmakers hold annual shareholder meetings.In these meetings,
Liveome, an affiliate of Medytox, said it completed the phase 1 clinical trial in Australia for its gene-recombinant microbiome drug, LIV001.The drug is being developed as a treatment for inflammatory bowel disease, a chronic immune disorder that has been challenging to manage with existing therapie
HK inno.N is embroiled in a crisis rumor after it lost the first round of patent litigation for the crystalline form of its P-CAB-based gastroesophageal reflux disease (GERD) drug, K-CAB Tab (tegoprazan).However, the company denied such concerns, expressing confidence about the continued growth of K
"Korea is known for its successful clinical trials. However, underneath it is Korea’s characteristics of frequently delayed reimbursement for new drugs. I think part of it is to ensure access to new drugs by participating in clinical trials."Ingrid A. Mayer, vice president of global clinical strateg
Korean pharmaceutical and biotechnology companies are set to present their latest studies at the American Association for Cancer Research (AACR) Annual Meeting 2024.The AACR meeting, established in 1907 and regarded as one of the world's top three cancer conferences alongside those of the American S
Hanmi Pharmaceutical said it has submitted an investigational new drug (IND) application for a phase 1 clinical trial of its obesity treatment candidate HM15275 to the Ministry of Food and Drug Safety (MFDS). Hanmi also plans to submit the IND application to the U.S. FDA this month.HM15275 is an obe